摘要
目的:探讨复方健胰胶囊治疗非酒精性脂肪肝病的临床疗效。方法:将符合纳入标准的60例患者按随机数字表法分为对照组和治疗组各30例,对照组采用常规西药治疗,治疗组在对照组基础上加用复方健胰胶囊治疗,1个月为1个疗程,治疗1个疗程后。比较治疗前后胰岛素抵抗指数(HOMA-IR)、胰岛素作用指数(IAI)、三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、谷氨酰基转移酶(GGT)、体质量指数(BMI)、腰臀比(WHR)等指标,比较两组患者治疗前后中医证候积分,并行安全性指标监测。结果:①两组治疗后HOMA-IR均有明显降低(P<0.01),两组IAI治疗后均有明显升高(P<0.01),两组治疗后比较,治疗组HOMAIR降低更明显(P<0.05),IAI升高更明显(P<0.01)。②两组在治疗后TG、TC、LDL-C均有降低(P<0.01),两组治疗后比较,治疗组指标降低更明显(P<0.05);两组在治疗后HDL-C均有升高(P<0.01),两组治疗后比较,治疗组HDL-C升高更明显(P<0.01)。③治疗组ALT、AST、GGT治疗后有明显降低(P<0.01),对照组治疗前后变化不明显(P>0.05);两组治疗后比较,治疗组指标降低明显(P<0.01)。④两组治疗前后,组内、组间BMI、WHR相比均无统计学差异(P>0.05)。⑤两组临床疗效比较,治疗组有效率为93.3%;对照组有效率为66.7%,两组有效率比较有显著性差异(P<0.01)。结论:复方健胰胶囊治疗非酒精性脂肪肝病疗效显著。
Objective To observe the clinical efficacy of Fufangjianyi Capsule in the treatment of non-alcoholic fatty liver disease. Meth- ods：60 cases were randomly divided into the control group and the treatment group, each of 30 cases. The control group was given rou- tine treatment, and the treatment group was given Fufangjianyi Capsule on the basis of the control group. One month as a course of treat- ment. Compared and analyzed the changes between pretherapy and post-treatment on the indexes of HOMA-IR, IAI, TG, TC, LDL-C, HDL-C, ALT, AST, GGT, BMI and WHR, etc. and compared the TCM symptoms score of the two groups before and after the treatment, and detected the safety indexes in the meantime. Results： ①After the treatment, HOMA-IR of both groups declined distinctly （P 〈 0. 01 ） ,and IAI increased obviously（ P 〈 0.01 ）, comparing the two groups after treatment, HOMA-IR of the treatment group dropped more obviously（P 〈0.01 ）, and IAI increased distinctly （P 〈 0.01 ） than those in the control group. ②TG, TC and LDL-C of both groups had declined after treatment（ P 〈 0.01 ） ,the indexes of treatment group dropped more obviously（ P 〈0.05 ）. HDL-C of both two groups increased significantly（ P 〈 0.01 ）, and the indexes of treatment group increased more obviously （ P 〈 0.01 ）. ③After the treat- ment, ALT, AST and GGT declined distinctly in the treatment group（ P 〈 0.01 ）, while the control group didn＇t have obviously changes （ P 〉 0.05 ） ; Comparing the two groups after treatment, the indexes in the treatment group dropped significantly （P 〈 0.01 ）. ④BMI, WHR of the two groups didn＇t have evident differences （ P 〉 0.05 ） before and after the treatment. ⑤The total effective rate of the treatment group was 93.3% and the control group was 66.7% ,the comparison of the total effective rate of both groups had significantly diversity （P 〈 0. 01 ）. Conclusion ： Fufangjianyi Capsule in treating the non-alcoholic fatty liver disease has significant curative effect.
出处
《中医学报》
CAS
2013年第12期1899-1902,共4页
Acta Chinese Medicine
基金
安徽中医药大学青年科学基金项目(编号:2012qn038)
关键词
非酒精性脂肪肝病
复方健胰胶囊
氨氯地平
non-alcoholic fatty liver disease
fufangjianyi capsule
amlodipine
